Subsequent in vivo validation of HOPX expression proved the efficacy of our approach, but also showed that weak SOX9‐dependent expression of HOPX is present in the DNE, although at lower levels compared to CH/FE. The gene discussed is SOX9; the disease is cyclic hematopoiesis.